PDE4C Antikörper (C-Term)

Produktnummer ABIN2750931

Dieser Kaninchen Polyklonal Antikörper detektiert spezifisch PDE4C in WB, ELISA, IHC, IP, IF, ICC und CM. Es zeigt Reaktivität gegenüber Proben von Human, Maus und Ratte. Es wurde in 9+ Publikationen zitiert.

Kurzübersicht für PDE4C Antikörper (C-Term) (ABIN2750931)

Target: PDE4C (phosphodiesterase 4C, CAMP-Specific (PDE4C))

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser PDE4C Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunoprecipitation (IP), Immunofluorescence (IF), Immunocytochemistry (ICC), Confocal Microscopy (CM)

Produktdetails anti-PDE4C Antikörper

Bindungsspezifität: C-Term

Aufreinigung: Affinity Purified

Immunogen: Synthetic cyclic carboxy-terminal peptide common to all PDE4C variants.

Isotyp: IgG

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 0.65 μg/μL

Referenzen für anti-PDE4C Antikörper (ABIN2750931)

Cheng, Wu, He, Liu, Jia, Di, Ji: "siRNA-mediated silencing of phosphodiesterase 4B expression affects the production of cytokines in endotoxin-stimulated primary cultured microglia." in: Experimental and therapeutic medicine, Vol. 12, Issue 4, pp. 2257-2264, (2017) (PubMed).

Ji, Di, He, Liu, Liu, Li, Zhang: "Intrathecal injection of phosphodiesterase 4B-specific siRNA attenuates neuropathic pain in rats with L5 spinal nerve ligation." in: Molecular medicine reports, Vol. 13, Issue 2, pp. 1914-22, (2016) (PubMed).

Massimi, Cardarelli, Galli, Giardi, Ragusa, Panera, Cinque, Cifone, Biagioni, Giorgi: "Increase of Intracellular Cyclic AMP by PDE4 Inhibitors Affects HepG2 Cell Cycle Progression and Survival." in: Journal of cellular biochemistry, Vol. 118, Issue 6, pp. 1401-1411, (2016) (PubMed).

Petersen, Kristensen, Jeppesen, Grøndahl, Wissing, Macklon, Andersen: "Distribution and function of 3',5'-Cyclic-AMP phosphodiesterases in the human ovary." in: Molecular and cellular endocrinology, Vol. 403, pp. 10-20, (2015) (PubMed).

Yougbaré, Boire, Roy, Lugnier, Rouseau: "NCS 613 exhibits anti-inflammatory effects on PBMCs from lupus patients by inhibiting p38 MAPK and NF-κB signalling pathways while reducing proinflammatory cytokine production." in: Canadian journal of physiology and pharmacology, Vol. 91, Issue 5, pp. 353-61, (2014) (PubMed).

Abusnina, Alhosin, Keravis, Muller, Fuhrmann, Bronner, Lugnier: "Down-regulation of cyclic nucleotide phosphodiesterase PDE1A is the key event of p73 and UHRF1 deregulation in thymoquinone-induced acute lymphoblastic leukemia cell apoptosis." in: Cellular signalling, Vol. 23, Issue 1, pp. 152-60, (2011) (PubMed).

Yougbare, Morin, Senouvo, Sirois, Albadine, Lugnier, Rousseau: "NCS 613, a potent and specific PDE4 inhibitor, displays anti-inflammatory effects on human lung tissues." in: American journal of physiology. Lung cellular and molecular physiology, Vol. 301, Issue 4, pp. L441-50, (2011) (PubMed).

Murray, Patel, Suda, Zhang, Thistlethwaite, Yuan, Insel: "Expression and activity of cAMP phosphodiesterase isoforms in pulmonary artery smooth muscle cells from patients with pulmonary hypertension: role for PDE1." in: American journal of physiology. Lung cellular and molecular physiology, Vol. 292, Issue 1, pp. L294-303, (2007) (PubMed).

Gallagher, Bacon, Odumeru, Gallagher, Fitzpatrick, Regan: "Valproate activates phosphodiesterase-mediated cAMP degradation: relevance to C6 glioma G1 phase progression." in: Neurotoxicology and teratology, Vol. 26, Issue 1, pp. 73-81, (2004) (PubMed).

Details zu PDE4C

Target: PDE4C (phosphodiesterase 4C, CAMP-Specific (PDE4C))

Andere Bezeichnung: PDE4C

UniProt: Q08493

Pathways: Negative Regulation of Hormone Secretion, cAMP Metabolic Process